MDNA - Medicenna Presents Preclinical Data on MDNA113 its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | Benzinga
Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics
MDNA113 is a first-in-class IL-13R?2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes
IL-13R?2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patients
TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data demonstrating proof of concept for the Company's novel T-MASK (Targeted Metallo/protease Activated SuperKine) platform technology with the Company's development candidate, MDNA113, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") held in San Diego, CA, from November 1-5, 2023.
"We are pleased to show preclinical data demonstrating the ability of our T-MASK platform to enhance tumor specific accumulation, increased anti-tumor activity while improving the safety profile of potent immune modulators such as Medicenna's bispecific IL-2-AntiPD1 Superkine," said Fahar Merchant, Ph.D., President and Chief Executive Officer of Medicenna. "The results presented today demonstrates proof of concept with MDNA113, our first T-MASK candidate specifically designed to deliver bispecific IL-2-antiPD1 Superkine to cancers that express the tumor associate antigen, IL-13R?2. This is an important advance for cancer immunotherapy as the IL13Ra2 target is linked to aggressive cancers that annually affect over 2 million patients world-wide."
The Company selected MDNA113, a novel, first-in-class tumor-targeted and tumor-activated bi-specific antiPD1-IL-2 Superkine as its first development candidate using the T-MASK platform. MDNA113 has high selectivity and affinity for the IL-13 decoy receptor IL-13R?2, a tumor associated antigen expressed by many aggressive solid tumors. MDNA113 is fused ...